Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.77 |
| ▸ | NPC1 | O15118 | 9/20 | 0.77 |
| ▸ | RAB9A | P51151 | 8/20 | 0.77 |
| ▸ | MAPT | P10636 | 5/20 | 0.77 |
| ▸ | POLB | P06746 | 4/20 | 0.77 |
| ▸ | GAA | P10253 | 2/20 | 0.77 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.73 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | GFER | P55789 | 1/20 | 0.73 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.73 |
| ▸ | RELA | Q04206 | 1/20 | 0.73 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.71 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | CASP3 | P42574 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875397 | 0.87 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL10455797 | 0.87 | MEN1 (0.69) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL16291121 | 0.86 | MEN1 (0.71) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL2683478 | 0.86 | EPHX1 (1.00) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL30640703 | 0.86 | EPHX1 (1.00) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL1514839 | 0.84 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL7980937 | 0.84 | EPHX1 (0.81) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL10458447 | 0.84 | KDM4E (0.72) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL16291120 | 0.83 | MAPK14 (1.00) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL10712301 | 0.83 | MEN1 (0.76) | MEN1KMT2ANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2007087424-A2 | METHOD OF TREATING KCNQ RELATED DISORDERS USING ORGANOZINC COMPOUNDS | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-0972010-A1 | USE OF THE ANTIBACTERIAL ACTIVE SUBSTANCE TRICLOCARBANE IN LIQUID SOAPS | BAYER AG (DE) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998042820-A1 | USE OF THE ANTIBACTERIAL ACTIVE SUBSTANCE TRICLOCARBANE IN LIQUID SOAPS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | KCNQ3, KCNQ1, KCNQ5 | MEN1 774/4885KMT2A 154/4885NPC1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.